QCG
SPRY icon

Quadrant Capital Group’s ARS Pharmaceuticals SPRY Stock Holding History

Quadrant Capital Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.79K Hold
347
– – ﹤0.01% 2464
2025
Q4 		$4.04K Hold
347
– – ﹤0.01% 2414
2025
Q3 		$3.49K Buy
+347
New +$4.98K ﹤0.01% 2388
2025
Q2 		– Sell
-347
Closed -$4.37K – 2450
2025
Q1 		$4.37K Hold
347
– – ﹤0.01% 2380
2024
Q4 		$3.66K Hold
347
– – ﹤0.01% 2379
2024
Q3 		$5.03K Hold
347
– – ﹤0.01% 2318
2024
Q2 		$2.95K Hold
347
– – ﹤0.01% 2415
2024
Q1 		$3.55K Hold
347
– – ﹤0.01% 2397
2023
Q4 		$1.9K Buy
+347
New +$1.52K ﹤0.01% 2483

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Quadrant Capital Group's SPRY Position: Q1 2026 in Review

Quadrant Capital Group held its ARS Pharmaceuticals (SPRY) position steady in Q1 2026 at 347 shares worth $2.79K. The position accounts for ﹤0.01% of the portfolio, ranked #2464.

Quadrant Capital Group first reported a position in SPRY in Q4 2023 and has held it in 9 quarters since. The position peaked at $5.03K in Q3 2024. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Quadrant Capital Group held 347 shares of ARS Pharmaceuticals worth $2.79K as of Q1 2026.
  • Quadrant Capital Group left its ARS Pharmaceuticals share count unchanged in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2464 holding.
  • Quadrant Capital Group first reported a position in ARS Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
  • Quadrant Capital Group's ARS Pharmaceuticals position peaked at $5.03K in Q3 2024.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.